Your browser doesn't support javascript.
loading
B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink, Beth A; Reddy, Sangeetha M; Gao, Jianjun; Zhang, Shaojun; Basar, Rafet; Thakur, Rohit; Yizhak, Keren; Sade-Feldman, Moshe; Blando, Jorge; Han, Guangchun; Gopalakrishnan, Vancheswaran; Xi, Yuanxin; Zhao, Hao; Amaria, Rodabe N; Tawbi, Hussein A; Cogdill, Alex P; Liu, Wenbin; LeBleu, Valerie S; Kugeratski, Fernanda G; Patel, Sapna; Davies, Michael A; Hwu, Patrick; Lee, Jeffrey E; Gershenwald, Jeffrey E; Lucci, Anthony; Arora, Reetakshi; Woodman, Scott; Keung, Emily Z; Gaudreau, Pierre-Olivier; Reuben, Alexandre; Spencer, Christine N; Burton, Elizabeth M; Haydu, Lauren E; Lazar, Alexander J; Zapassodi, Roberta; Hudgens, Courtney W; Ledesma, Deborah A; Ong, SuFey; Bailey, Michael; Warren, Sarah; Rao, Disha; Krijgsman, Oscar; Rozeman, Elisa A; Peeper, Daniel; Blank, Christian U; Schumacher, Ton N; Butterfield, Lisa H; Zelazowska, Monika A; McBride, Kevin M; Kalluri, Raghu.
Afiliação
  • Helmink BA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bhelmink@mdanderson.org.
  • Reddy SM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao J; Department of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Basar R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thakur R; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yizhak K; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Sade-Feldman M; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Blando J; Broad Institute of the Massachusetts Institute of Technology, Boston, MA, USA.
  • Han G; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gopalakrishnan V; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xi Y; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhao H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Amaria RN; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cogdill AP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu W; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • LeBleu VS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kugeratski FG; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel S; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Arora R; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Woodman S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Keung EZ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gaudreau PO; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Reuben A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spencer CN; Department of Thoracic / Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burton EM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Haydu LE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lazar AJ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zapassodi R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hudgens CW; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ledesma DA; Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ong S; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bailey M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Warren S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rao D; Nanostring Technologies, Seattle, WA, USA.
  • Krijgsman O; Nanostring Technologies, Seattle, WA, USA.
  • Rozeman EA; Nanostring Technologies, Seattle, WA, USA.
  • Peeper D; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blank CU; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schumacher TN; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Butterfield LH; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zelazowska MA; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • McBride KM; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kalluri R; Departments of Medicine, Surgery, Immunology and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA.
Nature ; 577(7791): 549-555, 2020 01.
Article em En | MEDLINE | ID: mdl-31942075
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Carcinoma de Células Renais / Estruturas Linfoides Terciárias / Imunoterapia / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Carcinoma de Células Renais / Estruturas Linfoides Terciárias / Imunoterapia / Melanoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos